目前,全世界至少有2.5亿人是HBV感染者~([1]),这些感染者存在极大的风险发展成为肝纤维化、肝硬化和肝细胞癌,导致每年大约65万人死亡~([2])。乙肝疫苗问世以来,虽然可以减少每年新增HBV感染人数,但HBV感染人口基数大,目前又无有效的根治手段,HBV感染至今仍是一个严重的公共卫生问题。经国家食品药品监督管理局批准用于抗HBV治疗的药物主要有两大类:IFN和核苷(酸)类似物 At present, at least 250 million people in the world are infected with HBV ([1]). These people are at an extremely high risk of developing liver fibrosis, cirrhosis and hepatocellular carcinoma, resulting in approximately 650,000 deaths annually [2]). Since the advent of hepatitis B vaccine, although the number of new HBV infections can be reduced each year, the number of HBV-infected population is large and no effective cure is available at present. HBV infection is still a serious public health problem. There are two main categories of drugs approved by the State Food and Drug Administration for anti-HBV therapy: IFN and nucleoside (acid) analogs